RxDoctor Payments Data

Laura Read, NP

Nurse Practitioner · Mandeville, LANPI 1619431830

Payments from drug & device makers

$637in general payments, 2019–2025

Across 14 payments — averaging $45.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$243
  • Abbott$174
  • AstraZeneca$84
  • Amgen$38
  • Exact Sciences$22
  • Dexcom, Inc.$21
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$243
Abbott3$174
AstraZeneca1$84
Amgen2$38
Exact Sciences1$22
Dexcom, Inc.1$21
Bayer1$21
Pfizer1$17
Sanofi1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$637 in reported general payments places this provider in the 60th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,055
Medicare patients
92
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$21,331
Lagevrio (Eua)Molnupiravir21$12,623
SynthroidLevothyroxine Sodium21$1,783
PaxlovidNirmatrelvir/Ritonavir22$1,429
Levothyroxine Sodium81$812
Pantoprazole Sodium61$775
Albuterol Sulfate HfaAlbuterol Sulfate23$765
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$724
Bupropion XlBupropion Hcl15$659
Escitalopram Oxalate22$642
Esomeprazole Magnesium11$474
Rosuvastatin Calcium49$408
Omeprazole21$375
Losartan Potassium49$361
Gabapentin24$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$243$21,33116 claims
PfizerPaxlovid$17$1,42922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →